Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Amgen to see $1billion a year from AMG-531

Amgen to see $1billion a year from AMG-531

3rd November 2005

Amgen’s novel therapy AMG-531 and Ligand Pharmaceuticals/GlaxoSmithKline’s SB-497115 will attain peak year sales of up to $1 billion and $500 million, respectively, according to a new report.

The drugs are used for the treatment of thrombocytopenia, a major side effect of chemotherapy. Thrombocytopenia is the reduction of the platelet (thrombocyte) count in the blood. A condition that occurs when platelets are lost from circulation faster than the bone marrow can replace them.

Entitled Managing the Side Effects of Chemotherapy, the report focuses on the five major side effects of chemotherapy treatment: thrombocytopenia, chemotherapy-induced anemia, neutropenia, oral mucositis, and chemotherapy-induced nausea and vomiting, and finds that the market for chemotherapy-related hematological toxicities (thrombocytopenia anemia, and neutropenia) was $6.3 billion in 2004 and will grow to $10.3 billion in 2014.

Mary Argent-Katwala, analyst at Decision Resources, which carried out the study, said that Amgen, Johnson & Johnson, and Roche will continue to dominate the marketplace.

However, she adds that the launch of Amgen’s AMG-531 and Ligand Pharmaceuticals/GlaxoSmithKline’s SB-497115 will “revolutionise” the thrombocytopenia market.

She said this was down to the fact that both companies are expected to implement education and marketing campaigns that will produce an eightfold increase in drug-treatment rates for thrombocytopenia.

“Many of the physicians we surveyed indicated that thrombocytopenia is almost impossible to treat effectively using current methods,” said Ms Argent-Katwala.

track© Adfero Ltd

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.